Melphalan

Old and new uses of a still master drug for multiple myeloma

Pellegrino Musto, Fiorella D'Auria

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents. Melphalan still remains as a reference drug for combination regimens, including emerging newer therapeutic options, either used at a standard dose for initial or salvage treatments in patients who are not eligible for more intensive therapies, or in conjunction with new molecules within high-dose chemotherapy programs. In this review, the authors analyze old and novel regimens, including melphalan for the treatment of newly diagnosed or relapsed/resistant patients with multiple myeloma in the clinical settings of standard chemotherapy, as well as autologous or allogeneic stem cell transplantation.

Original languageEnglish
Pages (from-to)1467-1487
Number of pages21
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number9
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Melphalan
Multiple Myeloma
Stem Cell Transplantation
Pharmaceutical Preparations
Drug Therapy
Salvage Therapy
Drug Combinations
Therapeutics

Keywords

  • Bortezomib
  • Lenalidomide
  • Melphalan
  • Multiple myeloma
  • Stem cell transplantation
  • Thalidomide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Melphalan : Old and new uses of a still master drug for multiple myeloma. / Musto, Pellegrino; D'Auria, Fiorella.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 9, 09.2007, p. 1467-1487.

Research output: Contribution to journalArticle

Musto, Pellegrino ; D'Auria, Fiorella. / Melphalan : Old and new uses of a still master drug for multiple myeloma. In: Expert Opinion on Investigational Drugs. 2007 ; Vol. 16, No. 9. pp. 1467-1487.
@article{3bbbf5d0f8204868bb050b74fc1f864f,
title = "Melphalan: Old and new uses of a still master drug for multiple myeloma",
abstract = "The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents. Melphalan still remains as a reference drug for combination regimens, including emerging newer therapeutic options, either used at a standard dose for initial or salvage treatments in patients who are not eligible for more intensive therapies, or in conjunction with new molecules within high-dose chemotherapy programs. In this review, the authors analyze old and novel regimens, including melphalan for the treatment of newly diagnosed or relapsed/resistant patients with multiple myeloma in the clinical settings of standard chemotherapy, as well as autologous or allogeneic stem cell transplantation.",
keywords = "Bortezomib, Lenalidomide, Melphalan, Multiple myeloma, Stem cell transplantation, Thalidomide",
author = "Pellegrino Musto and Fiorella D'Auria",
year = "2007",
month = "9",
doi = "10.1517/13543784.16.9.1467",
language = "English",
volume = "16",
pages = "1467--1487",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Melphalan

T2 - Old and new uses of a still master drug for multiple myeloma

AU - Musto, Pellegrino

AU - D'Auria, Fiorella

PY - 2007/9

Y1 - 2007/9

N2 - The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents. Melphalan still remains as a reference drug for combination regimens, including emerging newer therapeutic options, either used at a standard dose for initial or salvage treatments in patients who are not eligible for more intensive therapies, or in conjunction with new molecules within high-dose chemotherapy programs. In this review, the authors analyze old and novel regimens, including melphalan for the treatment of newly diagnosed or relapsed/resistant patients with multiple myeloma in the clinical settings of standard chemotherapy, as well as autologous or allogeneic stem cell transplantation.

AB - The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents. Melphalan still remains as a reference drug for combination regimens, including emerging newer therapeutic options, either used at a standard dose for initial or salvage treatments in patients who are not eligible for more intensive therapies, or in conjunction with new molecules within high-dose chemotherapy programs. In this review, the authors analyze old and novel regimens, including melphalan for the treatment of newly diagnosed or relapsed/resistant patients with multiple myeloma in the clinical settings of standard chemotherapy, as well as autologous or allogeneic stem cell transplantation.

KW - Bortezomib

KW - Lenalidomide

KW - Melphalan

KW - Multiple myeloma

KW - Stem cell transplantation

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=34548564435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548564435&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.9.1467

DO - 10.1517/13543784.16.9.1467

M3 - Article

VL - 16

SP - 1467

EP - 1487

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 9

ER -